ISPOR - Budget Impact Analysis of Erlotib as the First-Line Therapy of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in Vietnam

Full Text

Budget Impact Analysis of Erlotib as the First-Line Therapy of Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in Vietnam

Abstract

Authors

TT Tran T Nguyen

Back to Volume 19, Issue 3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now